Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational, multicenter, retrospective study assessing blastic plasmacytoid dendritic cell neoplasm treated with Tagraxofusp in the european expanded access program

Next Previous
Trial Profile

An observational, multicenter, retrospective study assessing blastic plasmacytoid dendritic cell neoplasm treated with Tagraxofusp in the european expanded access program

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tagraxofusp (Primary)
  • Indications Blastic plasmacytoid dendritic cell neoplasm
  • Focus Adverse reactions; Expanded access; Therapeutic Use

Most Recent Events

  • 13 Dec 2022 Results (n=22; on a database extraction date of June 30, 2022) assessing efficacy and safety of patients with blastic plasmacytoid dendritic cell neoplasm treated with tagraxofusp, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 01 Oct 2022 Preliminary results published in the Clinical Lymphoma, Myeloma & Leukemia
  • 13 Aug 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top